A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
| Autor: | Tryfonidis, K., Boukovinas, I., Xenidis, N., Christophyllakis, C., Papakotoulas, P., Politaki, E., Malamos, N., Polyzos, A., Kakolyris, S., Georgoulias, V., Mavroudis, D. |
|---|---|
| Zdroj: | In The Breast December 2013 22(6):1171-1177 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect